DiaMedica Therapeutics (DMAC) Payables (2017 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Payables of $3.3 million for Q1 2026, up 118.51% year-over-year from $1.5 million in Q1 2025, and up 123.25% quarter-over-quarter from $1.5 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Payables (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Payables history runs 10 years deep, the most recent figure standing at $3.3 million for Q1 2026.
- In Q1 2026, Payables rose 118.51% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 118.51% YoY), while the FY2025 annual figure was $1.5 million, up 56.91% from the prior year.
- Payables for Q1 2026 stood at $3.3 million, up from $1.5 million in the prior quarter.
- The five-year high for Payables was $3.3 million in Q1 2026, with the low at $433000.0 in Q1 2022.
- The 5-year median for Payables is $926000.0 (2023), against an average of $1.2 million.
- The sharpest annual moves came in 2023 and 2024: Payables soared 311.09% in 2023, then tumbled 59.78% in 2024.
- DiaMedica Therapeutics' Payables stood at $734000.0 in 2022, then advanced by 26.16% to $926000.0 in 2023, then gained by 1.51% to $940000.0 in 2024, then surged by 56.91% to $1.5 million in 2025, then surged by 123.25% to $3.3 million in 2026.
- Business Quant data shows DMAC's Payables at $3.3 million in Q1 2026, $1.5 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 2.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.81 Mn |
| Mar 31, 2026 | 3.29 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.92 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 940,000.00 |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 759,000.00 |
| Mar 31, 2024 | 716,000.00 |
| Dec 31, 2023 | 926,000.00 |
| Sep 30, 2023 | 863,000.00 |
| Jun 30, 2023 | 856,000.00 |
| Mar 31, 2023 | 1.78 Mn |
| Dec 31, 2022 | 734,000.00 |
| Sep 30, 2022 | 864,000.00 |
| Jun 30, 2022 | 624,000.00 |
| Mar 31, 2022 | 433,000.00 |
| Dec 31, 2021 | 509,000.00 |
| Sep 30, 2021 | 699,000.00 |